Bionano Genomics, Inc. (BNGO) |
| 1.18 0.05 (4.42%) 04-13 16:00 |
| Open: | 1.13 |
| High: | 1.18 |
| Low: | 1.125 |
| Volume: | 107,371 |
| Market Cap: | 4(M) |
| PE Ratio: | -0.24 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 1.47 |
| Resistance 1: | 1.32 |
| Pivot price: | 1.19 |
| Support 1: | 1.08 |
| Support 2: | 0.90 |
| 52w High: | 5.5 |
| 52w Low: | 1.06 |
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
| EPS | -4.850 |
| Book Value | 4.140 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.189 |
| Profit Margin (%) | -92.59 |
| Operating Margin (%) | -107.36 |
| Return on Assets (ttm) | -27.7 |
| Return on Equity (ttm) | -66.2 |
Sun, 12 Apr 2026
Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2025 earnings call transcript - MSN
Tue, 24 Mar 2026
Bionano Genomics, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:BNGO) 2026-03-24 - Seeking Alpha
Mon, 23 Mar 2026
Bionano Genomics Inc (BNGO) Q4 2025 Earnings Call Highlights: Na - GuruFocus
Mon, 23 Mar 2026
Bionano Genomics (BNGO) Earnings Transcript - The Globe and Mail
Mon, 23 Mar 2026
Earnings call transcript: Bionano Genomics’ Q4 2025 results show cost cuts, stock surges - Investing.com
Mon, 09 Feb 2026
Global scientists converge online to map genomes at Bionano’s 4-day summit - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |